[Pharmacological modification of traumatic edemas in animal experiment and clinic].
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007611:Aprotinin / Q000627:therapeutic use; D002918:Chymotrypsin / Q000627:therapeutic use; D003345:Corticosterone / Q000627:therapeutic use; D003864:Depression, Chemical; D004121:Dimethyl Sulfoxide / Q000627:therapeutic use; D004195:Disease Models, Animal; D004487:Edema / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D006493:Heparin / Q000627:therapeutic use; D006496:Heparinoids / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008784:Methysergide / Q000627:therapeutic use; D009824:Ointments; D010653:Phenylbutazone / Q000627:therapeutic use; D051381:Rats; D013268:Stimulation, Chemical; D013978:Tibial Fractures / Q000188:drug therapy; D013997:Time Factors; D014947:Wounds and Injuries / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D006496:Heparinoids; D006634:Histamine H1 Antagonists; D009824:Ointments; D006493:Heparin; D007611:Aprotinin; D002918:Chymotrypsin; D010653:Phenylbutazone; D003345:Corticosterone; D008784:Methysergide; D004121:Dimethyl Sulfoxide
Die pharmakologische Beeinflussing von traumatischen ödemen in tierexperiment und Klinik.